Cytori Therapeutics Inc (CYTX)
(Delayed Data from NSDQ)
$0.29 USD
+0.02 (5.56%)
Updated May 3, 2019 04:00 PM ET
After-Market: $0.28 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Plus Therapeutics, Inc. [CYTX]
Reports for Purchase
Showing records 1 - 20 ( 200 total )
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Termination of Coverage due to the departure from the firm of the covering analyst
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEDE K
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EU Filing for ATI-0918 in 2019; Data Possible in Scleroderma in France and SUI in Japan in 1H19; Lowering PT to $3
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ValuEngine Detailed Valuation Report for CYTX
Provider: ValuEngine, Inc
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cytori Receives Orphan Designation for ATI-1123
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Catalysts Lay Ahead, but a Rising Share Count Lowers Our PT to $5.00 from $6.00
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cytori Reports ED Data; Reverses the Stock 1 for 10 and Is Raising Capital Too; While We Wait for a Partnership on Azaya
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Full-Year Plan Outlined; Focus on ATI-0918 and Japan
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Liposomal Doxorubicin Could Be the Means, Habeo Should Be the End Game -Initiating Coverage
Provider: H.C. Wainwright & Co., Inc.
Analyst: KOLBERT J
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage due to the departure of the covering analyst.
Provider: Roth Capital Partners, Inc.
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ROTH Healthcare Monthly - Longing for Better Blood at ASH
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Continued Movement to Build the Revenue Line
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
STAR Enrolled; MAP Blocking Tackling Continues
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q16 Results; Looking to MAP Traction; Target Split-Adjusted to $11
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Halfway There on Pivotal and E.U. Path Gets a Boost; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2015 Results; Data, Cost Controls and Global Reach; Strong Foundation
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Plus Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.